Atai Life Sciences Valuation

Is 9VC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9VC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 9VC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 9VC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9VC?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 9VC. This is calculated by dividing 9VC's market cap by their current preferred multiple.
What is 9VC's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

9VC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	349.8x
Enterprise Value/EBITDA	-1.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 9VC's PB Ratio compare to its peers?

The above table shows the PB ratio for 9VC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	4.2x
APPH Apontis Pharma	2.6x	77.1%	€81.5m
2FJ0 Pierrel	3.6x	n/a	€92.8m
HIGH Cantourage Group	1.3x	110.6%	€56.1m
PSG PharmaSGP Holding	9.1x	14.6%	€297.4m
9VC Atai Life Sciences	1.3x	35.4%	€198.0m

Price-To-Book vs Peers: 9VC is good value based on its Price-To-Book Ratio (1.3x) compared to the peer average (4.2x).

Price to Earnings Ratio vs Industry

How does 9VC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.9%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: 9VC is good value based on its Price-To-Book Ratio (1.3x) compared to the European Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 9VC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9VC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9VC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9VC forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€1.23	€8.41 +586.1%	43.5%	€13.64	€4.55	n/a	4
Nov ’25	€0.99	€8.41 +748.8%	43.5%	€13.64	€4.55	n/a	4
Oct ’25	€1.01	€8.41 +734.9%	43.5%	€13.64	€4.55	n/a	4
Sep ’25	€1.18	€8.41 +612.9%	43.5%	€13.64	€4.55	n/a	4
Aug ’25	€1.39	€8.77 +533.0%	39.7%	€13.85	€5.54	n/a	4
Jul ’25	€1.23	€10.89 +788.4%	48.4%	€19.38	€5.54	n/a	5
Jun ’25	€1.45	€10.89 +653.2%	48.4%	€19.38	€5.54	n/a	5
May ’25	€1.83	€10.89 +495.5%	48.4%	€19.38	€5.54	n/a	5
Apr ’25	€1.82	€13.36 +634.0%	43.2%	€19.34	€5.53	n/a	4
Mar ’25	€1.86	€11.58 +521.9%	53.5%	€19.26	€4.68	n/a	5
Feb ’25	€1.65	€11.58 +603.1%	53.5%	€19.26	€4.68	n/a	5
Jan ’25	€1.39	€11.58 +735.2%	53.5%	€19.26	€4.68	n/a	5
Dec ’24	€1.02	€11.39 +1,020.1%	50.1%	€19.36	€4.70	n/a	6
Nov ’24	€1.16	€11.38 +878.7%	47.3%	€19.65	€4.77	€0.99	7
Oct ’24	€1.23	€11.38 +822.4%	47.3%	€19.65	€4.77	€1.01	7
Sep ’24	€1.41	€10.55 +648.7%	49.0%	€19.25	€4.67	€1.18	8
Aug ’24	€1.87	€11.05 +492.4%	40.9%	€18.93	€4.60	€1.39	10
Jul ’24	€1.46	€11.04 +658.0%	40.7%	€19.37	€4.70	€1.23	11
Jun ’24	€1.64	€11.04 +571.5%	40.7%	€19.37	€4.70	€1.45	11
May ’24	€1.74	€10.86 +522.7%	40.7%	€19.06	€4.63	€1.83	11
Apr ’24	€1.56	€10.96 +602.5%	39.1%	€19.37	€4.70	€1.82	12
Mar ’24	€1.50	€11.74 +680.4%	37.3%	€19.38	€4.71	€1.86	12
Feb ’24	€1.63	€11.74 +621.9%	37.3%	€19.38	€4.71	€1.65	12
Jan ’24	€2.32	€20.77 +795.2%	46.1%	€47.11	€6.22	€1.39	13
Dec ’23	€3.21	€22.70 +607.0%	46.9%	€49.06	€6.48	€1.02	12
Nov ’23	€3.21	€23.58 +634.3%	46.0%	€50.61	€6.68	€1.16	12

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.